[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.120.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1980

γ-Acetylenic GABA in Tardive Dyskinesia

Author Affiliations

From Departments H (Drs Casey, Gerlach, and Christensen), and E (Dr Magelund), Set Hans Hospital, Roskilde, Denmark, and the Departments of Medical Research, Psychiatry, and Neurology (Dr Casey), Veterans Administration Medical Center and University of Oregon Health Sciences Center, Portland.

Arch Gen Psychiatry. 1980;37(12):1376-1379. doi:10.1001/archpsyc.1980.01780250062007
Abstract

• Brain γ-aminobutyric acid (GABA) has been proposed to play a role in the modulation of extrapyramidal motor function. The effects of increasing brain GABA with γ-acetylenic GABA (GAG), a drug that inhibits GABA transaminase, were evaluated in ten patients with stable tardive dyskinesia during a blind placebo-controlled trial. Drug effects during active treatment and two placebo periods were evaluated by scoring randomly sequenced videotapes of tardive dyskinesia and parkinsonian symptoms recorded weekly during a standardized examination. Tardive dyskinesia was significantly reduced, and preexisting parkinsonism increased slightly. The largest decrease in tardive dyskinesia symptoms occurred in patients receiving higher neuroleptic doses, suggesting an interaction between GABA and dopamine. Prolactin values increased but growth hormone values were unchanged. Psychiatric symptoms were also unchanged during GAG treatment.

×